Brain tumor News
Sponsored By
Monteris Laser Therapy For Brain Tumors
Please Click On The Above Banner For More Details
Braintumor Website

Brain Tumor Related News!
Fundraisers For Brain Tumor Research!
Brain Tumor Conferences / Events
New Clinical Trials
Noteworthy Treatments Explanation of the new high tech treatments!

Conferences / Events

  • No events scheduled. Please check back soon!

Brain Tumor News!

Displaying Stories 1 to 20 of 6,128
Next 20

03/21/17 VBI Vaccines Building On Duke University Research for New Cancer Therapy        

 This is an exciting new treatment. IF it is true that most GBMs have the CMV virus, this vaccine should work.  As I mentioned in recent stories, it is controversial if that is true.  A few researcher say almost all GBMs have it and a few others say NO GBM have it.  If this vaccine works, it is more proof of that theory.

03/20/17 Is it time for "Conditional Approvals"?        

 I have been working on this plan for a while, but I think now is the time for it to actually be approved. Everything is coming together - like the perfect storm:

1. We finally have a few experimental treatments in the pipeline that look really good.

2. The new president is slashing regulations and calling for faster FDA approvals and for slashing drug prices.

3. Computer technology  and biostatistics have reached the point where our plan for a registry trial can be just as reliable - maybe more so - than traditional phase 3 trials.

IF this plan is put into effect, I predict we would have an immediate breakthrough in the treatment of brain tumors, and the possibility of a cure in a few years, instead of the decades it would take on the current path.

I need the support of other organizations now, and in a few weeks I may need everyone to be writing letters and making phone calls.  I will send out details when it is time!

03/17/17 Antibody treats pediatric brain tumors safely and effectively in mice        

 Let's hope this gets into human trials quickly

03/17/17 Medicenna BioPharma Announces Strategic Collaboration with MD Anderson Cancer Center to Advance Next Generation Empowered Cytokines™        

 Early results were very impressive.  This is a different type of immunotherapy that does not depend on the body creating antibodies.  It is an old treatment that was hampered in the past by an inability to get the drug where it is needed.  With modern equipment, it is now possible to get it exactly where it is needed and it should do a lot better. I will be keeping an eye on this trial!

Disclosure: This company is a sponsor of our organization.

03/17/17 Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.        

 This article says that using more than 6 months of Temozolomide is not better than using 6 months of it as far as survival goes. That is counter-intuitive.  I would like to see larger studies to confirm it.

03/10/17 Trump Chooses Dr. Scott Gottlieb To Head Food And Drug Administration        

 Sounds like a great pick!  I have been working on a plan to speed up drug approvals for brain tumors - and slash the price of new drugs.  Maybe Dr Gottlieb would be open to the idea of helping brain tumor patients.  Does anyone happen to have a connection to him?   Let me know!

03/10/17 Clinical Trial Announcement Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Glioblastoma at First Recurrence or Progression        

 Disclosure: the company that makes this is a sponsor of the Musella Foundation

This is an exciting trial.  It is similar (although it uses a different target) to a trial done a long time ago that failed because the state of the art in convection enhanced delivery at that time did not allow the drug to get to the entire tumor.  Now the technology has improved to the point where it can deliver the drug to just about anywhere we want it to go!  A major advantage of this type of treatment over other immunotherapies is that it does not rely on your immune system to help it. The fusion protein binds to the IL-4 receptor (which about 80% of glioblastomas over-express, and normal cells do not express), and carried the toxin to those cells - which makes this a smart bomb type of approach - it should theoretically kill tumor cells and not normal cells.


 This is a fun way to raise money for brain tumor research. Part of the proceeds goes to the Musella Foundation!

03/10/17 Role of MGMT Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications.        

 Good project, but I disagree with their conclusion.  They found that 25% of the time, the methylation status changes between the first and second surgery.   They conclude that it is insignificant and we shouldn't bother testing the second time as it provides no useful information.  They are correct for now, but  that should change very shortly as there is now a drug in clinical trials that can work on unmethylated patients. This makes the methylation status very important to determine, and for those 25% of patients with the changed status, it can be a life altering test.

03/10/17 Ependymoma Awareness Day.        

 From our good friends at the CERN foundation!

03/09/17 Absence of cytomegalovirus in glioblastoma and other high-grade gliomas by real-time PCR, immunohistochemistry and in situ hybridization        

 This is a hot topic.  Some researchers are reporting 100% of GBMs have cytomegalovirus. Other researchers are reporting none have it. I would love to see a roundtable discussion with both groups getting together, discuss the methods they use, and finally figure it out. It has profound consequences.  Some early results of targeting CMV in small trials has showed some success, so I lean toward the group that says there is CMV in GBMs.  More research is needed.

03/08/17 Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children set to open soon        

 This is the polio vaccine treatment for brain tumors that was covered in 2 60 minutes episodes. Very exciting. And I am so proud to announce that the Musella Foundation played a role in getting this trial started for children aged 12-18.  The listing names us as a "sponsor and collaborator"!

It should open soon.


03/08/17 Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients.        

 General consensus is that Optune is now the standard of care for newly diagnosed GBM patients, and a good option for recurrent GBM patients!

03/07/17 Help us better Understand Patient Experiences with Glioblastoma Multiforme        

 I am sending this out again as they still have a few more spots open.  It is an easy way to make $125!  We heard back from some of our members who tried it and they did get the money, and we also got a donation from them.

02/26/17 Renowned Neuro-oncologist Joining Northwestern        

 One of my favorites neuro-oncs is coming to the USA.  He twice changed the standard of care for GBMs. Hopefully he will have more resources at Northwestern to speed up the search for the cure. I welcome him and wish him luck!


02/23/17 Tocagen Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Toca 511 & Toca FC in Recurrent High Grade Glioma        

 This is very exciting news. I have always felt that it is almost criminal that most patients do not have access to treatments like this.  They have shown that the treatment is safe, and early results show impressive results - at least a doubling of average survival with some patients still doing perfectly for a long time.  This breakthrough therapy designation will speed up the process of approval.  It opens the possibility  that FDA approval could come based on the phase 2 trial which has completely enrollment and results should be available within a year, which means that FDA approval might be possible by the end of next year.  Unfortunately not soon enough for anyone who has a brain tumor now. We still have to work on ways to make it available now to people who need it - possibly using compassionate use or the right to try laws.


02/22/17 UPDATED: Agenus’ lead cancer vaccine flops, investigators read last rites over glioblastoma PhII        

 Unfortunately, this trial failed. It may have failed because the vaccine was started too late - at the time of recurrence. It makes a lot more sense to try it for newly diagnosed healthier patients.  Adding in a checkpoint inhibitor should also help. Lastly, with other vaccines, the early readings of the trial did not look good, but as time goes on, there was a small group of patients who do well for a much longer time than expected.

02/21/17 Help us better Understand Patient Experiences with Glioblastoma Multiforme        

 This is a survey from a market research group.  If you participate in a phone call, they will send you $125, and the Musella Foundation also gets a donation!    This is only for GBM patients or people who care for a gbm patient.

  Let me know if you participate!

02/09/17 VBI Vaccines Building On Duke University Research for New Cancer Therapy        

Exciting.  Early trials of the vaccine looked good.

Displaying Stories 1 to 20 of 6128
Next 20

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2017 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557

Website Design By
World Wide Websites